Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 123

Sort by

Sort Order Select

Journal Articles

Mutation Profile of PPM1D and TP53 in Patients with Myelodysplastic Syndromes and Complex Chromosome Abnormalities

Blood (2019) 134 (Supplement_1): 2994.

https://doi.org/10.1182/blood-2019-126778

Published: 2019

Journal Articles

Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Emma Verner, MBBS, BMedSci,FRCPA, FRACP, Amanda Johnston, FRACP,FRCPA,MBBS,BMBS,MD, Nalini Pati, MBBS,FRACP,FRCPA, DCH, MD DNB, Eliza A Hawkes, Hui-Peng Lee, MBChB, FRACP, FRCPA, BHB, Tara Cochrane, MBBS,FRCPA,FRACP, Chan Y. Cheah, Duncan Purtill, MBBS,FRCPA,FRACP, Anoop K Enjeti, MBBS,FRCPA, FRACP,PhDMD,MRCP, Christina Brown, PhDFRACP,FRCPA,MBBS, Nicholas E. Murphy, FRCPA,MBBS,FRACP, Jennifer Curnow, MBBS, FRACP, FRCPA, PhD, Julia Carlson, Belinda Butcher, BSci, MBiostat, PhD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4094.

https://doi.org/10.1182/blood-2019-124621

Published: 2019

Journal Articles

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Locke J. Bryan, MD, Scott E. Smith, MD PhD, Pamela Allen, MDMSc, Carla Casulo, Brett Alan Palmer, BS, Reem Karmali, MD, Barbara Pro, MD, Denise M Scholtens, PhD, Hatice Savas, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 4029.

https://doi.org/10.1182/blood-2019-123879

Published: 2019

Journal Articles

Predictive Value of Cellular Blood Indices for All-Cause Mortality in Acute Pulmonary Embolism

Brett Slajus, Yevgeniy Brailovsky, DO, Trung Phan, Iman Darwish, Jawed Fareed, PhD, Amir Darki, MD MSc

Blood (2019) 134 (Supplement_1): 2103.

https://doi.org/10.1182/blood-2019-127425

Published: 2019

Journal Articles

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Christie P.M. Verkleij, MD, Monique C. Minnema, Okke de Weerdt, MD, Patricia W.C. Bosman, MSc, Kristine A. Frerichs, MD, Alexandra J. Croockewit, MD PhD, Saskia K. Klein, MD PhD, Gerard Bos, MD PhD, Tuna Mutis, Wouter J. Plattel, MD, Ellen van der Spek, MD PhD, Annemiek Broyl, MD PhD, Pieter Sonneveld, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Niels W. C. J. Van De Donk, MD PhD

Blood (2019) 134 (Supplement_1): 1879.

https://doi.org/10.1182/blood-2019-124339

Published: 2019

Journal Articles

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2019) 134 (Supplement_1): 761.

https://doi.org/10.1182/blood-2019-121521

Published: 2019

Journal Articles

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blood (2019) 134 (Supplement_1): 762.

https://doi.org/10.1182/blood-2019-122451

Published: 2019

Journal Articles

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Blood (2019) 134 (Supplement_1): 861.

https://doi.org/10.1182/blood-2019-127992

Published: 2019

Journal Articles

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Youngsook Choi, MD, Jeanne Mendell, PhD MPH, Ruth Namuyinga, MD MPH, Hoang Pham, PharmD, Nabil Said, MD MPH, Yibin Wang, PhD, Tsvetomir Mitov, MD, Ben Kim, PharmD, Samer K. Khaled, MD

Blood (2019) 134 (Supplement_1): 1372.

https://doi.org/10.1182/blood-2019-121762

Published: 2019

Journal Articles

KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208)

Madan Jagasia, MBBS, MS, MMHC, Amandeep Salhotra, MD, Carlos R. Bachier, MD, Behyar Zoghi, MD, PhD, FACP, Aleksandr Lazaryan, MDPhDMPH, Daniel J. Weisdorf, MD, James Essell, MD, Laurie S. Green, MD, Olivier Schueller, PhD, Lindy Huang, Zhongming Yang, PhD, David Eiznhamer, PhD, Sanjay K. Aggarwal, MD, Bruce R. Blazar, MD, Stephanie J. Lee, MD MPH

Blood (2019) 134 (Supplement_1): 872.

https://doi.org/10.1182/blood-2019-125986

Published: 2019

Journal Articles

The Safety of Novel Drugs Targeting Factor XI and XII in Human Clinical Trials:a Systematic Review

Gillian E Mair, Sven Reid Olson, MD, Joseph J Shatzel, MD

Blood (2019) 134 (Supplement_1): 4966.

https://doi.org/10.1182/blood-2019-130823

Published: 2019

Journal Articles

Efficacy of Fecal Microbiota Transplant in Hematological Cancers Patients with Recurrent Clostridioides Difficile Infection: A Systemic Review and Meta-Analysis

Raseen Tariq, MBBS, Fateeha Furqan, MD, Saad Jamshed, MD, Sahil Khanna, MBBS

Blood (2019) 134 (Supplement_1): 5870.

https://doi.org/10.1182/blood-2019-131431

Published: 2019

Journal Articles

Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Blood (2019) 134 (Supplement_1): 285.

https://doi.org/10.1182/blood-2019-126977

Published: 2019

Journal Articles

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Kelly S. Chien, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Naval G. Daver, MD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Elias Jabbour, MD, Michael Andreeff, MD PhD, Yesid Alvarado, MD, Prithviraj Bose, MD, Nitin Jain, MD, Kimberly Sheppard, BSN, RN, Cheri Klingner-Winton, Sherry A. Pierce, BSN, BA, Xiao Qin Dong, Kelly Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4240.

https://doi.org/10.1182/blood-2019-129598

Published: 2019

Journal Articles

The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials

M. Judith Peterschmitt, MD, Selena Freisens, MD, Audrey W Hou, PharmD, Lisa Underhill, MS, Meredith C. Foster, ScD, Sebastiaan J.M. Gaemers, MD

Blood (2018) 132 (Supplement 1): 3692.

https://doi.org/10.1182/blood-2018-99-118319

Published: 2018

Journal Articles

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Michael Byrne, MD, Mark G. Frattini, MD PhD, Oliver G. Ottmann, MD, Ioannis Mantzaris, MD MS, Martin Wermke, MD, Daniel J. Lee, MD, Daniel Morillo, MD, Arne Scholz, PhD, Stuart Ince, PhD, Ray Valencia, MD, Fabricio Souza, MD, Raul Cordoba, MD PhD

Blood (2018) 132 (Supplement 1): 4055.

https://doi.org/10.1182/blood-2018-99-117257

Published: 2018

Journal Articles

Safety and Efficacy of Non-Irradiated Granulocyte Transfusions (GTX) in Neutropenic Patients with Severe or Refractory Abdominal Infections: A Single Center Retrospective Analysis of 119 Transfusions in 22 Patients

Guillaume Richard-Carpentier, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Courtney D. DiNardo, MD MSc, William G. Wierda, MD PhD, Naval G. Daver, MD, Naveen Pemmaraju, MD, Prithviraj Bose, MD, Marina Y. Konopleva, MD PhD, Michael Andreeff, MD PhD, Srdan Verstovsek, MD PhD, Heidi M Krause, Fleur M. Aung, MD, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 3815.

https://doi.org/10.1182/blood-2018-99-119702

Published: 2018

Journal Articles

MLL-Menin Inhibition Reverses Pre-Leukemic Progenitor Self-Renewal Induced By NPM1 Mutations and Prevents AML Development

Hannah J. Uckelmann, PhD, Stephanie M. Kim, BA, Noa J. C. Antonissen, Andrei V. Krivtsov, PhD, Charles Hatton, Gerard M. McGeehan, PhD, Ross L. Levine, MD, George S. Vassiliou, Scott A. Armstrong, MD PhD

Blood (2018) 132 (Supplement 1): 546.

https://doi.org/10.1182/blood-2018-99-110851

Published: 2018

Journal Articles

Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning

Blood (2018) 132 (Supplement 1): 604.

https://doi.org/10.1182/blood-2018-99-110124

Published: 2018

Journal Articles

Phase I/II Study of Ruxolitinib for Minimal Residual Disease in Chronic Myeloid Leukemia

Abhishek Maiti, MBBS, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Rebecca Poku, MPH, Brittany A Yearby, Stephanie Breakefield, RN, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 3009.

https://doi.org/10.1182/blood-2018-99-113972

Published: 2018

NARROW

Mutation Profile of PPM1D and TP53 in Patients with Myelodysplastic Syndromes and Complex Chromosome Abnormalities

Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Predictive Value of Cellular Blood Indices for All-Cause Mortality in Acute Pulmonary Embolism

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208)

The Safety of Novel Drugs Targeting Factor XI and XII in Human Clinical Trials:a Systematic Review

Efficacy of Fecal Microbiota Transplant in Hematological Cancers Patients with Recurrent Clostridioides Difficile Infection: A Systemic Review and Meta-Analysis

Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Safety and Efficacy of Non-Irradiated Granulocyte Transfusions (GTX) in Neutropenic Patients with Severe or Refractory Abdominal Infections: A Single Center Retrospective Analysis of 119 Transfusions in 22 Patients

MLL-Menin Inhibition Reverses Pre-Leukemic Progenitor Self-Renewal Induced By NPM1 Mutations and Prevents AML Development

Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning

Phase I/II Study of Ruxolitinib for Minimal Residual Disease in Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only